Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer
Clinical trial NCT02551263 · COMPLETED
Trial details
- NCT number
- NCT02551263
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2015-07-22
- Primary completion
- 2020-07-01
- Enrollment
- 201
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.